Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out
March20 podcast Dr Hazen
anti-TMA pill in a year or 2 ? (scroll 12 mins)

Additional info:
MEBO Karen
at UK Findacure conf 2020

Scroll down and select country

MEBO Map Testing & Meetups

Full details :
want listed ? contact

MEBO - UBIOME study 2018



MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person


Participation info : LINK English

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts



TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned

Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
NORD Member Organization
See RareConnect

Popular Posts (last 30 days)

Upcoming get-togethers

Let us know if you want a meetup listed

Subscribe to Blog

Enter your email address:

Delivered by FeedBurner

You will be sent a verification email

Subscribe in a reader

Blog Archive

MEBO Research Clinical Trials

Click here to read details of the MEBO Clinical Trials
NCT03582826 - Ongoing not recruiting
Microbial Basis of Systemic Malodor and PATM Conditions (PATM)
United States 2018 - ongoing

NCT02683876 - Completed
Exploratory Study of Relationships Between Malodor and Urine Metabolomics
Canada and United States 2016 - ongoing

NCT03451994 - Completed
Exploratory Study of Volatile Organic Compounds in Alveolar Breath
United Kingdom and United States 2013 - ongoing

NCT02692495 - Completed
Evaluation of Potential Screening Tools for Metabolic Body Odor and Halitosis
United Kingdom 2009 - 2012

Monday, September 24, 2012

TMAU/FMO3 webinar recording : Professors Shephard and Phillips

2ND Webinar on FMO3

This is the recording of the TMAU/FMO3 webinar that took place 23rd September 2012
Guest Speakers : Professor Elizabeth Shephard and Professor Ian Phillips
Webinar title : "FMO3 : bugs, genes and drugs"

The webinar was kindly hosted by Rob Pleticha of
You can see the original post on here : TMAU webinar has a TMAU community : TMAU community

This is the first in a series of webinars with TMAU/FMO3 experts as guest speakers. There was also a previous webinar where TMAU sufferer, MEBO UK Director of Public Relations, Karen gave a talk on how to use the media to advance the Cause of people living with malodour disorders: Karen's TMAU talk.

SUPPORT THE MEBO MISSION: Click Amazon button at right sidebar of this blog when shopping online at no extra cost to you.
MEBO gets small commission from Amazon.

Use your credit card
to make your donation.

A EURORDIS and NORD Member Organization 


Betty Wolcott said...

This excellent webinar enabled me to do a more informed set of internet searches on FMO3.

Question: if selenocysteine can override UGA stop codes, would it work on FMO3 mutations in the same way as Ataluren to alleviate TMAU symptoms? (Selenocysteine is available on Amazon.)

Thank you so much.

Oct 8, 2012, 2:16:00 AM
blogcontributor2 said...

Hi Betty

I don't know the answer to your question but it seems that people with nonsense mutations ('false stops') usually make up a small % of a 'deficiency' community. Usually about 5-10% (and nonsense mutations are usually very severe). So even if selenocysteine worked it would only work for say 5-10% of the community.

I guess there is probably a reason it won't work anyway, or they would be using that ?

Oct 11, 2012, 9:58:00 PM
blogcontributor2 said...

Hi Betty

Professor Shephard emailed a reply to me. Here it is :

There are ongoing clinical trials for cystic fibrosis where chemicals that allow stop mutations to be by-passed are being tested. If these prove successful then such treatments could be used for other disorders caused by stop codon mutations. However, it turns out that the base sequence on either side of the stop codon are really important in how well this approach works.

No clinical trials have been carried out to show that selenocysteine will overcome stop codon mutations. Such trials would have to be done on a protein by protein basis. Because each protein has a specific amino acid order. This order and identity of the amino acids is crucial for the protein to adopt a precise 3-dimensional structure.

Oct 27, 2012, 10:15:00 AM
Post a Comment